Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice First published 25/03/2024 Last updated 01/08/2025 EU PAS number:EUPAS1000000083 Study Finalised